May 7th 2024
Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Strong Efficacy and Safety Data Observed With Telisotuzumab Vedotin for c-Met+ NSCLC
April 16th 2021A promising objective response rate and a tolerable safety profile were observed with telisotuzumab vedotin monotherapy to treat patients with previously treated c-Met–positive advanced non–small cell lung cancer.
Phase 3 Trial of Tumor-Treating Fields for NSCLC Impresses at Interim Analysis
April 15th 2021Interim analysis of the phase 3 LUNAR trial led to a data monitoring committee recommendation to reduce the trial sample size due to strongly positive results gathered from the current patient population treated with tumor-treating fields.
Improved PFS and OS Correlated With Undetectable METex14 Following Savolitinib in NSCLC
April 11th 2021Patients with non‒small cell lung cancer with undetectable circulating tumor MET Exon 14 following treatment with savolitinib are more likely to have positive progression-free and overall survival outcomes.
Investigational RET Inhibitor TPX-0046 Show Preliminary Clinical Activity in NSCLC, MTC
April 6th 2021In a dose-finding trial, TPX-0046 elicited responses in patients with non–small cell lung cancer and medullary thyroid cancer who were naïve to prior tyrosine kinase inhibitors and whose tumors harbored alterations in RET.
Updated Data Support Significant Clinical Benefit of Entrectinib in ROS1 Fusion+ NSCLC
April 5th 2021Data from the Journal of Clinical Oncology found that entrectinib resulted in high-level clinical benefit for patients with ROS1 fusion–positive non–small cell lung cancer, regardless of CNS metastases status.
Phase 3 Trial of Adjuvant Atezolizumab in Resectable NSCLC Meets DFS End Point
March 22nd 2021Results of the phase 3 IMpower010 trial have demonstrated that adjuvant atezolizumab for patients with stage IB to IIIA non–small cell lung cancer leads to increased disease-free survival versus best supportive care for patients with high PD-L1.
Frontline Cemiplimab Monotherapy Improved Overall, Progression-Free Survival for High PD-L1 NSCLC
March 1st 2021Data published in The Lancet found that the PD-L1 inhibitor cemiplimab improved overall and progression-free survival for patients with advanced non–small cell lung cancer with PD-L1 of at least 50%.
FDA Approves Cemiplimab as First-Line Treatment for Advanced, High PD-L1 NSCLC
February 22nd 2021The approval of cemiplimab in non–small cell lung cancer was supported by results from the phase 3 EMPOWER-Lung 1 trial that investigated its use as monotherapy in the first-line setting compared with platinum-doublet chemotherapy in patients with locally advanced or metastatic disease whose tumor cells expressed PD-L1.
Salma Jabbour, MD, on the Results of the Ongoing KEYNOTE-799 Study
February 17th 2021The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
FDA Grants Priority Review to Sotorasib to Treat Patients With KRAS G12C–Mutated NSCLC
February 17th 2021Amgen announced that their new drug application for sotorasib was granted priority review by the FDA to treat patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.
Adjuvant Osimertinib Does Not Adversely Affect Health-Related QOL for EGFR+ NSCLC
February 15th 2021Patients with EGFR-positive non–small cell lung cancer who received treatment with osimertinib following surgery versus placebo experienced no clinically meaningful differences in health-related quality of life, according to results of a pivotal phase 3 trial.
Jonathan Thompson, MD, MS, on AEs and Limitations Reported in the Phase 2 BGBC008 Study
February 15th 2021The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.
Jonathan Thompson, MD, MS, on the Impact of the Phase 2 BGBC008 Study Results
February 8th 2021The ongoing phase 2 BGBC008 trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI-refractory composite AXL-positive non–small cell lung cancer.
HER3-Directed Antibody Therapy May Be an Effective Strategy in EGFR+ NSCLC
February 3rd 2021Patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, appeared to be effective at the recommended expansion dose of 5.6 mg/kg in patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer based on clinically meaningful antitumor activity and a manageable safety profile.